A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: Changing species specificity by substitution of a single residue

Biochemical Journal

Volumn 412, Issue 3, 2008, Pages 447-457

  Andersen, Lisbeth M ^a   Wind, Troels ^a   Hansen, Hanne D ^a   Andreasen, Peter A ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Cancer; Metastasis; Peptide; Phage display; Serine protease; Urokinase type plasminogen activator (uPA)

Indexed keywords

DRUG THERAPY; MICROFLUIDICS;

CHEMICALLY SYNTHESIZED; CHROMOGENIC SUBSTRATES; IN ORDER; MURINE CANCER MODELS; PATHOLOGICAL CONDITIONS; PEPTIDE LIBRARIES; PEPTIDE SEQUENCING; PLASMINOGEN (PG); SINGLE RESIDUE; UROKINASE TYPE PLASMINOGEN ACTIVATOR (UPA);

AMINES;

ALANINE; AMINO ACID DERIVATIVE; CHROMOGENIC SUBSTRATE; CYCLOPEPTIDE; DISULFIDE; MUPAIN 1; PEPTIDE LIBRARY; TRYPSIN; UROKINASE;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITOR INTERACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME STRUCTURE; MUTAGENESIS; NONHUMAN; PEPTIDE SYNTHESIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEINASE INHIBITION; RAT; SPECIES DIFFERENCE; SURFACE PLASMON RESONANCE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MICE; PEPTIDES, CYCLIC; SPECIES SPECIFICITY; URINARY PLASMINOGEN ACTIVATOR;

MURINAE;

EID: 45349091918     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20071646     Document Type: Article

References (30)

1. Hedstrom, L. (2002) Serine protease mechanism and specificity. Chem. Rev. 102, 4501-4524
2. Barrett, A. J., Rawlings, N. D. and Woessner, J. F. (1998) Handbook of Proteolytic Enzymes, Academic Press, London
3. Dano, K., Moller, V., Ossowski, L. and Nielsen, L. S. (1980) Purification and characterization of a plasminogen activator from mouse cells transformed by an oncogenic virus. Biochim. Biophys. Acta 613, 542-555
4. Dano, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S. and Skriver, L. (1985) Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44, 139-266
5. Andreasen, P. A., Egelund, R. and Petersen, H. H. (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 57, 25-40
6. Andreasen, P. A., Kjoller, L., Christensen, L. and Duffy, M. J. (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72, 1-22
7. Kaltoft, K., Nielsen, L. S., Zeuthen, J. and Dano, K. (1982) Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme. Proc. Natl. Acad. Sci. U.S.A. 79, 3720-3723
8. Petersen, H.H., Hansen, M., Schousboe, S. L. and Andreasen, P. A. (2001) Localization of epitopes tor monoclonal antibodies to urokinase-type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme. Eur. J. Biochem. 268, 4430-4439
9. Laboissiere, M. C., Young, M. M., Pinho, R. G., Todd, S., Fletterick, R. J., Kuntz, I. and Craik, C. S. (2002) Computer-assisted mutagenesis of ecotin to engineer its secondary binding site for urokinase inhibition. J. Biol. Chem. 277, 26623-26631
10. Mackman, R. L., Katz, B. A., Breitenbucher, J. G., Hui, H. C., Verner, E., Luong, C., Liu, L. and Sprengeler, P. A. (2001) Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator. J. Med. Chem. 44, 3856-3871
11. Schweinitz, A., Steinmetzer, T., Banke, I. J., Arlt, M. J., Sturzebecher, A., Schuster, O., Geissler, A., Giersiefen, H., Zeslawska, E., Jacob, U. et al. (2004) Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J. Biol. Chem. 279, 33613-33622
12. Spencer, J. B., McGee, D., Allen, D., Katz, B. A., Luong, C., Sendzik, M., Sguires, N. and Mackman, R. L. (2002) 4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors. Bioorg. Med. Chem. Lett. 12, 2023-2026
13. Sperl, S., Jacob, U., Arroyo de Prada, N., Sturzebecher, J., Wilhelm, O. G., Bode, W., Magdolen, V., Huber, R. and Moroder, L. (2000) (4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase. Proc. Natl. Acad. Sci. U.S.A. 97, 5113-5118
14. Wendt, M. D., Rockway, T. W., Geyer, A., McClellan, W., Weitzberg, M., Zhao, X., Mantei, R., Nienaber, V. L., Stewart, K., Klinghofer, V. and Giranda, V. L. (2004) Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution. J. Med. Chem. 47, 303-324
15. Zeslawska, E., Jacob, U., Schweinitz, A., Coombs, G., Bode, W. and Madison, E. (2003) Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors. J. Mol. Biol. 328, 109-118
16. Frese, K. K. and Tuveson, D. A. (2007) Maximizing mouse cancer models. Nat. Rev. Cancer 7, 645-658
17. Dano, K., Nielsen, L. S., Moller, V. and Engelhart, M. (1980) Inhibition of a plasminogen activator from oncogenic virus-transformed mouse cells by rabbit antibodies against the enzyme. Biochim. Biophys. Acta 630, 146-151
18. Klinghofer, V., Stewart, K., McGonigal, T., Smith, R., Sarthy, A., Nienaber, V., Butler, C., Dorwin, S., Richardson, P., Weitzberg, M. et al. (2001) Species specificity of amidine-based urokinase inhibitors. Biochemistry 40, 9125-9131
19. Hansen, M., Wind, T., Blouse, G. E., Christensen, A., Petersen, H. H., Kjelgaard, S., Mathiasen, L., Holtet, T. L. and Andreasen, P. A. (2005) A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition. J. Biol. Chem. 280, 38424-38437
20. Zhao, G., Yuan, C., Wind, T., Huang, Z., Andreasen, P. A. and Huang, M. (2007) Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1. J. Struct. Biol. 160, 1-10
21. Kvassman, J. O., Verhamme, I. and Shore, J. D. (1998) Inhibitory mechanism of serpins: loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1. Biochemistry 37, 15491-15502
22. Olson, S. T., Bock, P. E., Kvassman, J., Shore, J. D., Lawrence, D. A., Ginsburg, D. and Bjork, I. (1995) Role of the catalytic serine in the interactions of serine proteinases with protein inhibitors of the serpin family. Contribution of a covalent interaction to the binding energy of serpin-proteinase complexes. J. Biol. Chem. 270, 30007-30017
23. Koivunen, E., Wang, B., Dickinson, C. D. and Ruoslahti, E. (1994) Peptides in cell adhesion research. Methods Enzymol. 245, 346-369
24. Scott, J. K. and Smith, G. P. (1990) Searching for peptide ligands with an epitope library. Science 249, 386-390
25. Jensen, J. K., Wind, T. and Andreasen, P. A. (2002) The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand. FEBS Lett. 521, 91-94
26. Wind, T., Jensen, J. K., Dupont, D. M., Kulig, P. and Andreasen, P. A. (2003) Mutational analysis of plasminogen activator inhibitor-1. Eur. J. Biochem. 270, 1680-1688
27. Larsen, K. S., Ostergaard, H., Bjelke, J. R., Olsen, O. H., Rasmussen, H. B., Christensen, L., Kragelund, B. B. and Stennicke, H. R. (2007) Engineering the substrate and inhibitor specificities of human coagulation Factor VIIa. Biochem. J. 405, 429-438
28. Diamond, S. (2007) Methods for mapping protease specificity. Curr. Opin. Chem. Biol. 11, 46-51
29. Ladner, R. C., Sato, A. K., Gorzelany, J. and de Souza, M. (2004) Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discovery Today 9, 525-529
30. Schwede, T., Kopp, J., Guex, N. and Peitsch, M. C. (2003) SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 31, 3381-3385